<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39302109</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1470-8728</ISSN><JournalIssue CitedMedium="Internet"><Volume>481</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>The Biochemical journal</Title><ISOAbbreviation>Biochem J</ISOAbbreviation></Journal><ArticleTitle>Lipoprotein(a) and cardiovascular disease.</ArticleTitle><Pagination><StartPage>1277</StartPage><EndPage>1296</EndPage><MedlinePgn>1277-1296</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1042/BCJ20240037</ELocationID><Abstract><AbstractText>Elevated plasma levels of lipoprotein(a) (Lp(a)) are a prevalent, independent, and causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease. Lp(a) consists of a lipoprotein particle resembling low density lipoprotein and the covalently-attached glycoprotein apolipoprotein(a) (apo(a)). Novel therapeutics that specifically and potently lower Lp(a) levels are currently in advanced stages of clinical development, including in large, phase 3 cardiovascular outcomes trials. However, fundamental unanswered questions remain concerning some key aspects of Lp(a) biosynthesis and catabolism as well as the true pathogenic mechanisms of the particle. In this review, we describe the salient biochemical features of Lp(a) and apo(a) and how they underlie the disease-causing potential of Lp(a), the factors that determine plasma Lp(a) concentrations, and the mechanism of action of Lp(a)-lowering drugs.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boffa</LastName><ForeName>Michael B</ForeName><Initials>MB</Initials><Identifier Source="ORCID">0000-0003-1211-3064</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Robarts Research Institute, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koschinsky</LastName><ForeName>Marlys L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Robarts Research Institute, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Biochem J</MedlineTA><NlmUniqueID>2984726R</NlmUniqueID><ISSNLinking>0264-6021</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017270">Lipoprotein(a)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017270" MajorTopicYN="Y">Lipoprotein(a)</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="N">Atherosclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">apolipoprotein(a)</Keyword><Keyword MajorTopicYN="N">atherosclerotic cardiovascular disease</Keyword><Keyword MajorTopicYN="N">calcific aortic valve disease</Keyword><Keyword MajorTopicYN="N">lipoprotein metabolism</Keyword><Keyword MajorTopicYN="N">lipoprotein(a)</Keyword><Keyword MajorTopicYN="N">thrombosis</Keyword></KeywordList><CoiStatement>M.B. Boffa has no competing interests to declare. M.L. Koschinsky holds a research contract with Eli Lilly &amp; Co. and is a consultant for Novartis and Eli Lilly &amp; Co.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>21</Day><Hour>13</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>21</Day><Hour>13</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>20</Day><Hour>8</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39302109</ArticleId><ArticleId IdType="pmc">PMC11555715</ArticleId><ArticleId IdType="doi">10.1042/BCJ20240037</ArticleId><ArticleId IdType="pii">234991</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Berg, K. (1963) A new serum type system in man&#x2013;the Lp system. Acta Pathol. Microbiol. Scand. 59, 369&#x2013;382 10.1111/j.1699-0463.1963.tb01808.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1699-0463.1963.tb01808.x</ArticleId><ArticleId IdType="pubmed">14064818</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke, R., Peden, J.F., Hopewell, J.C., Kyriakou, T., Goel, A., Heath, S.C.et al. (2009) Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361, 2518&#x2013;2528 10.1056/NEJMoa0902604</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0902604</ArticleId><ArticleId IdType="pubmed">20032323</ArticleId></ArticleIdList></Reference><Reference><Citation>Erqou, S., Kaptoge, S., Perry, P.L., Di Angelantonio, E., Thompson, A., White, I.R.et al. (2009) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302, 412&#x2013;423 10.1001/jama.2009.1063</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2009.1063</ArticleId><ArticleId IdType="pmc">PMC3272390</ArticleId><ArticleId IdType="pubmed">19622820</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamstrup, P.R., Tybjaerg-Hansen, A., Steffensen, R. and Nordestgaard, B.G. (2009) Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301, 2331&#x2013;2339 10.1001/jama.2009.801</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2009.801</ArticleId><ArticleId IdType="pubmed">19509380</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanassoulis, G., Campbell, C.Y., Owens, D.S., Smith, J.G., Smith, A.V., Peloso, G.M.et al. (2013) Genetic associations with valvular calcification and aortic stenosis. N. Engl. J. Med. 368, 503&#x2013;512 10.1056/NEJMoa1109034</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1109034</ArticleId><ArticleId IdType="pmc">PMC3766627</ArticleId><ArticleId IdType="pubmed">23388002</ArticleId></ArticleIdList></Reference><Reference><Citation>Fless, G.M., ZumMallen, M.E. and Scanu, A.M. (1986) Physicochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein (a). J. Biol. Chem. 261, 8712&#x2013;8718 10.1016/S0021-9258(19)84439-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(19)84439-3</ArticleId><ArticleId IdType="pubmed">2941420</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorey, M.B., Youssef, A., Aikas, L., Borrelli, M., Hermansson, M., Assini, J.M.et al. (2023) Lipoprotein(a) induces caspase-1 activation and IL-1 signaling in human macrophages. Front. Cardiovasc. Med. 10, 1130162 10.3389/fcvm.2023.1130162</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2023.1130162</ArticleId><ArticleId IdType="pmc">PMC10244518</ArticleId><ArticleId IdType="pubmed">37293282</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean, J.W., Tomlinson, J.E., Kuang, W.J., Eaton, D.L., Chen, E.Y., Fless, G.M.et al. (1987) cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330, 132&#x2013;137 10.1038/330132a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/330132a0</ArticleId><ArticleId IdType="pubmed">3670400</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsimikas, S., Fazio, S., Ferdinand, K.C., Ginsberg, H.N., Koschinsky, M.L., Marcovina, S.M.et al. (2018) NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J. Am. Coll. Cardiol. 71, 177&#x2013;192 10.1016/j.jacc.2017.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2017.11.014</ArticleId><ArticleId IdType="pmc">PMC5868960</ArticleId><ArticleId IdType="pubmed">29325642</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt, K., Noureen, A., Kronenberg, F. and Utermann, G. (2016) Structure, function, and genetics of lipoprotein (a). J. Lipid Res. 57, 1339&#x2013;1359 10.1194/jlr.R067314</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.R067314</ArticleId><ArticleId IdType="pmc">PMC4959873</ArticleId><ArticleId IdType="pubmed">27074913</ArticleId></ArticleIdList></Reference><Reference><Citation>Coassin, S. and Kronenberg, F. (2022) Lipoprotein(a) beyond the kringle IV repeat polymorphism: the complexity of genetic variation in the LPA gene. Atherosclerosis 349, 17&#x2013;35 10.1016/j.atherosclerosis.2022.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2022.04.003</ArticleId><ArticleId IdType="pmc">PMC7613587</ArticleId><ArticleId IdType="pubmed">35606073</ArticleId></ArticleIdList></Reference><Reference><Citation>Enkhmaa, B. and Berglund, L. (2022) Non-genetic influences on lipoprotein(a) concentrations. Atherosclerosis 349, 53&#x2013;62 10.1016/j.atherosclerosis.2022.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2022.04.006</ArticleId><ArticleId IdType="pmc">PMC9549811</ArticleId><ArticleId IdType="pubmed">35606076</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronenberg, F., Mora, S., Stroes, E.S.G., Ference, B.A., Arsenault, B.J., Berglund, L.et al. (2022) Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur. Heart J. 43, 3925&#x2013;3946 10.1093/eurheartj/ehac361</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac361</ArticleId><ArticleId IdType="pmc">PMC9639807</ArticleId><ArticleId IdType="pubmed">36036785</ArticleId></ArticleIdList></Reference><Reference><Citation>Utermann, G., Menzel, H.J., Kraft, H.G., Duba, H.C., Kemmler, H.G. and Seitz, C. (1987) Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J. Clin. Invest. 80, 458&#x2013;465 10.1172/JCI113093</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI113093</ArticleId><ArticleId IdType="pmc">PMC442258</ArticleId><ArticleId IdType="pubmed">2956279</ArticleId></ArticleIdList></Reference><Reference><Citation>Albers, J.J., Kennedy, H. and Marcovina, S.M. (1996) Evidence that Lp[a] contains one molecule of apo[a] and one molecule of apoB: evaluation of amino acid analysis data. J. Lipid Res. 37, 192&#x2013;196 10.1016/S0022-2275(20)37647-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2275(20)37647-1</ArticleId><ArticleId IdType="pubmed">8820114</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson, R.A. and Williams, R.J. (1990) Solution structure of the kringle 4 domain from human plasminogen by 1H nuclear magnetic resonance spectroscopy and distance geometry. J. Mol. Biol. 212, 541&#x2013;552 10.1016/0022-2836(90)90330-O</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-2836(90)90330-O</ArticleId><ArticleId IdType="pubmed">2157850</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye, Q., Rahman, M.N., Koschinsky, M.L. and Jia, Z. (2001) High-resolution crystal structure of apolipoprotein(a) kringle IV type 7: insights into ligand binding. Protein Sci. 10, 1124&#x2013;1129 10.1110/ps.01701</Citation><ArticleIdList><ArticleId IdType="doi">10.1110/ps.01701</ArticleId><ArticleId IdType="pmc">PMC2374005</ArticleId><ArticleId IdType="pubmed">11369850</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitayat, S., Kanelis, V., Koschinsky, M.L. and Smith, S.P. (2007) Nuclear magnetic resonance (NMR) solution structure, dynamics, and binding properties of the kringle IV type 8 module of apolipoprotein(a). Biochemistry 46, 1732&#x2013;1742 10.1021/bi061814g</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi061814g</ArticleId><ArticleId IdType="pubmed">17263558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mochalkin, I., Cheng, B., Klezovitch, O., Scanu, A.M. and Tulinsky, A. (1999) Recombinant kringle IV-10 modules of human apolipoprotein(a): structure, ligand binding modes, and biological relevance. Biochemistry 38, 1990&#x2013;1998 10.1021/bi9820558</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi9820558</ArticleId><ArticleId IdType="pubmed">10026282</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandmark, J., Tigerstrom, A., Akerud, T., Althage, M., Antonsson, T., Blaho, S.et al. (2020) Identification and analyses of inhibitors targeting apolipoprotein(a) kringle domains KIV-7, KIV-10, and KV provide insight into kringle domain function. J. Biol. Chem. 295, 5136&#x2013;5151 10.1074/jbc.RA119.011251</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA119.011251</ArticleId><ArticleId IdType="pmc">PMC7152747</ArticleId><ArticleId IdType="pubmed">32132173</ArticleId></ArticleIdList></Reference><Reference><Citation>Santonastaso, A., Maggi, M., De Jonge, H. and Scotti, C. (2020) High resolution structure of human apolipoprotein (a) kringle IV type 2: beyond the lysine binding site. J. Lipid Res. 61, 1687&#x2013;1696 10.1194/jlr.RA120001023</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.RA120001023</ArticleId><ArticleId IdType="pmc">PMC7707183</ArticleId><ArticleId IdType="pubmed">32907988</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Hoek, Y.Y., Wittekoek, M.E., Beisiegel, U., Kastelein, J.J. and Koschinsky, M.L. (1993) The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms. Hum. Mol. Genet. 2, 361&#x2013;366 10.1093/hmg/2.4.361</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/2.4.361</ArticleId><ArticleId IdType="pubmed">8389224</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcovina, S.M., Hobbs, H.H. and Albers, J.J. (1996) Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Clin. Chem. 42, 436&#x2013;439 10.1093/clinchem/42.3.436</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinchem/42.3.436</ArticleId><ArticleId IdType="pubmed">8598109</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabel, B.R. and Koschinsky, M.L. (1995) Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a). Biochemistry 34, 15777&#x2013;15784 10.1021/bi00048a023</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi00048a023</ArticleId><ArticleId IdType="pubmed">7495809</ArticleId></ArticleIdList></Reference><Reference><Citation>Koschinsky, M.L., Tomlinson, J.E., Zioncheck, T.F., Schwartz, K., Eaton, D.L. and Lawn, R.M. (1991) Apolipoprotein(a): expression and characterization of a recombinant form of the protein in mammalian cells. Biochemistry 30, 5044&#x2013;5051 10.1021/bi00234a029</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi00234a029</ArticleId><ArticleId IdType="pubmed">2036372</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker, L., Webb, B.A., Chitayat, S., Nesheim, M.E. and Koschinsky, M.L. (2003) A ligand-induced conformational change in apolipoprotein(a) enhances covalent Lp(a) formation. J. Biol. Chem. 278, 14074&#x2013;14081 10.1074/jbc.M212855200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M212855200</ArticleId><ArticleId IdType="pubmed">12566443</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman, M.N., Becker, L., Petrounevitch, V., Hill, B.C., Jia, Z. and Koschinsky, M.L. (2002) Comparative analyses of the lysine binding site properties of apolipoprotein(a) kringle IV types 7 and 10. Biochemistry 41, 1149&#x2013;1155 10.1021/bi010964i</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi010964i</ArticleId><ArticleId IdType="pubmed">11802713</ArticleId></ArticleIdList></Reference><Reference><Citation>Koschinsky, M.L., Cote, G.P., Gabel, B. and van der Hoek, Y.Y. (1993) Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. J. Biol. Chem. 268, 19819&#x2013;19825 10.1016/S0021-9258(19)36587-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(19)36587-1</ArticleId><ArticleId IdType="pubmed">8366120</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormick, S.P., Ng, J.K., Taylor, S., Flynn, L.M., Hammer, R.E. and Young, S.G. (1995) Mutagenesis of the human apolipoprotein B gene in a yeast artificial chromosome reveals the site of attachment for apolipoprotein(a). Proc. Natl Acad. Sci. U.S.A. 92, 10147&#x2013;10151 10.1073/pnas.92.22.10147</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.22.10147</ArticleId><ArticleId IdType="pmc">PMC40753</ArticleId><ArticleId IdType="pubmed">7479743</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonen, A., Yang, X., Yeang, C., Alekseeva, E., Koschinsky, M., Witztum, J.L.et al. (2020) Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a). J. Lipid Res. 61, 1263&#x2013;1270 10.1194/jlr.RA120000830</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.RA120000830</ArticleId><ArticleId IdType="pmc">PMC7469883</ArticleId><ArticleId IdType="pubmed">32641432</ArticleId></ArticleIdList></Reference><Reference><Citation>Koschinsky, M.L. and Marcovina, S.M. (2004) Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr. Opin. Lipidol. 15, 167&#x2013;174 10.1097/00041433-200404000-00009</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00041433-200404000-00009</ArticleId><ArticleId IdType="pubmed">15017359</ArticleId></ArticleIdList></Reference><Reference><Citation>Belczewski, A.R., Ho, J., Taylor, Jr, F.B., Boffa, M.B., Jia, Z. and Koschinsky, M.L. (2005) Baboon lipoprotein(a) binds very weakly to lysine-agarose and fibrin despite the presence of a strong lysine-binding site in apolipoprotein(a) kringle IV type 10. Biochemistry 44, 555&#x2013;564 10.1021/bi048156p</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi048156p</ArticleId><ArticleId IdType="pubmed">15641780</ArticleId></ArticleIdList></Reference><Reference><Citation>Garner, B., Merry, A.H., Royle, L., Harvey, D.J., Rudd, P.M. and Thillet, J. (2001) Structural elucidation of the N- and O-glycans of human apolipoprotein(a): role of o-glycans in conferring protease resistance. J. Biol. Chem. 276, 22200&#x2013;22208 10.1074/jbc.M102150200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M102150200</ArticleId><ArticleId IdType="pubmed">11294842</ArticleId></ArticleIdList></Reference><Reference><Citation>Mooser, V., Marcovina, S.M., White, A.L. and Hobbs, H.H. (1996) Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J. Clin. Invest. 98, 2414&#x2013;2424 10.1172/JCI119055</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI119055</ArticleId><ArticleId IdType="pmc">PMC507694</ArticleId><ArticleId IdType="pubmed">8941661</ArticleId></ArticleIdList></Reference><Reference><Citation>Edelstein, C., Italia, J.A., Klezovitch, O. and Scanu, A.M. (1996) Functional and metabolic differences between elastase-generated fragments of human lipoprotein[a] and apolipoprotein[a]. J. Lipid Res. 37, 1786&#x2013;1801 10.1016/S0022-2275(20)39122-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2275(20)39122-7</ArticleId><ArticleId IdType="pubmed">8864963</ArticleId></ArticleIdList></Reference><Reference><Citation>Edelstein, C., Shapiro, S.D., Klezovitch, O. and Scanu, A.M. (1999) Macrophage metalloelastase, MMP-12, cleaves human apolipoprotein(a) in the linker region between kringles IV-4 and IV-5. Potential relevance to lipoprotein(a) biology. J. Biol. Chem. 274, 10019&#x2013;10023 10.1074/jbc.274.15.10019</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.15.10019</ArticleId><ArticleId IdType="pubmed">10187779</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergmark, C., Dewan, A., Orsoni, A., Merki, E., Miller, E.R., Shin, M.J.et al. (2008) A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J. Lipid Res. 49, 2230&#x2013;2239 10.1194/jlr.M800174-JLR200</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M800174-JLR200</ArticleId><ArticleId IdType="pubmed">18594118</ArticleId></ArticleIdList></Reference><Reference><Citation>Horkko, S., Bird, D.A., Miller, E., Itabe, H., Leitinger, N., Subbanagounder, G.et al. (1999) Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103, 117&#x2013;128 10.1172/JCI4533</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI4533</ArticleId><ArticleId IdType="pmc">PMC407862</ArticleId><ArticleId IdType="pubmed">9884341</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman, P., Horkko, S., Steinberg, D., Witztum, J.L. and Dennis, E.A. (2002) Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation. J. Biol. Chem. 277, 7010&#x2013;7020 10.1074/jbc.M108860200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M108860200</ArticleId><ArticleId IdType="pubmed">11744722</ArticleId></ArticleIdList></Reference><Reference><Citation>Berliner, J.A., Leitinger, N. and Tsimikas, S. (2009) The role of oxidized phospholipids in atherosclerosis. J. Lipid Res. 50, S207&#x2013;S212 10.1194/jlr.R800074-JLR200</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.R800074-JLR200</ArticleId><ArticleId IdType="pmc">PMC2674746</ArticleId><ArticleId IdType="pubmed">19059906</ArticleId></ArticleIdList></Reference><Reference><Citation>Milic, I., Melo, T., Domingues, M.R., Domingues, P. and Fedorova, M. (2015) Heterogeneity of peptide adducts with carbonylated lipid peroxidation products. J. Mass Spectrom. 50, 603&#x2013;612 10.1002/jms.3568</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jms.3568</ArticleId><ArticleId IdType="pubmed">25800198</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibundgut, G., Scipione, C., Yin, H., Schneider, M., Boffa, M.B., Green, S.et al. (2013) Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J. Lipid Res. 54, 2815&#x2013;2830 10.1194/jlr.M040733</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M040733</ArticleId><ArticleId IdType="pmc">PMC3770094</ArticleId><ArticleId IdType="pubmed">23828779</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzobo, K.E., Cupido, A.J., Mol, B.M., Stiekema, L.C.A., Versloot, M., Winkelmeijer, M.et al. (2024) Diacylglycerols and lysophosphatidic acid, enriched on lipoprotein(a), contribute to monocyte inflammation. Arterioscler. Thromb. Vasc. Biol. 44, 720&#x2013;740 10.1161/ATVBAHA.123.319937</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.123.319937</ArticleId><ArticleId IdType="pmc">PMC10880937</ArticleId><ArticleId IdType="pubmed">38269588</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawn, R., Patthy, L., Pesole, G. and Saccone, C. (1997) Apolipoproteins(a): a puzzling evolutionary story. J. Mol. Evol. 44, 234&#x2013;236 10.1007/PL00013141</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/PL00013141</ArticleId><ArticleId IdType="pubmed">9069184</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson, J.E., McLean, J.W. and Lawn, R.M. (1989) Rhesus monkey apolipoprotein(a). Sequence, evolution, and sites of synthesis. J. Biol. Chem. 264, 5957&#x2013;5965 10.1016/S0021-9258(18)83643-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)83643-2</ArticleId><ArticleId IdType="pubmed">2925643</ArticleId></ArticleIdList></Reference><Reference><Citation>Chenivesse, X., Huby, T., Wickins, J., Chapman, J. and Thillet, J. (1998) Molecular cloning of the cDNA encoding the carboxy-terminal domain of chimpanzee apolipoprotein(a): an Asp57 &#x2013;&gt; Asn mutation in kringle IV-10 is associated with poor fibrin binding. Biochemistry 37, 7213&#x2013;7223 10.1021/bi9721546</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi9721546</ArticleId><ArticleId IdType="pubmed">9585533</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawn, R.M., Boonmark, N.W., Schwartz, K., Lindahl, G.E., Wade, D.P., Byrne, C.D.et al. (1995) The recurring evolution of lipoprotein(a). Insights from cloning of hedgehog apolipoprotein(a). J. Biol. Chem. 270, 24004&#x2013;24009 10.1074/jbc.270.41.24004</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.270.41.24004</ArticleId><ArticleId IdType="pubmed">7592597</ArticleId></ArticleIdList></Reference><Reference><Citation>Rader, D.J., Cain, W., Zech, L.A., Usher, D. and Brewer, Jr, H.B. (1993) Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production. J. Clin. Invest. 91, 443&#x2013;447 10.1172/JCI116221</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI116221</ArticleId><ArticleId IdType="pmc">PMC287951</ArticleId><ArticleId IdType="pubmed">8432853</ArticleId></ArticleIdList></Reference><Reference><Citation>Rader, D.J., Cain, W., Ikewaki, K., Talley, G., Zech, L.A., Usher, D.et al. (1994) The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J. Clin. Invest. 93, 2758&#x2013;2763 10.1172/JCI117292</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI117292</ArticleId><ArticleId IdType="pmc">PMC294537</ArticleId><ArticleId IdType="pubmed">8201014</ArticleId></ArticleIdList></Reference><Reference><Citation>Boffelli, D., Zajchowski, D.A., Yang, Z. and Lawn, R.M. (1999) Estrogen modulation of apolipoprotein(a) expression. Identification of a regulatory element. J. Biol. Chem. 274, 15569&#x2013;15574 10.1074/jbc.274.22.15569</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.22.15569</ArticleId><ArticleId IdType="pubmed">10336452</ArticleId></ArticleIdList></Reference><Reference><Citation>Simony, S.B., Mortensen, M.B., Langsted, A., Afzal, S., Kamstrup, P.R. and Nordestgaard, B.G. (2022) Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: the Copenhagen General Population Study. Atherosclerosis 355, 76&#x2013;82 10.1016/j.atherosclerosis.2022.06.1023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2022.06.1023</ArticleId><ArticleId IdType="pubmed">35803767</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenner, J.L., Ordovas, J.M., Lamon-Fava, S., Schaefer, M.M., Wilson, P.W., Castelli, W.P.et al. (1993) Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation 87, 1135&#x2013;1141 10.1161/01.CIR.87.4.1135</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.87.4.1135</ArticleId><ArticleId IdType="pubmed">8462142</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang, Y. and Tian, W. (2017) The effects of progesterones on blood lipids in hormone replacement therapy. Lipids Health Dis. 16, 219 10.1186/s12944-017-0612-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12944-017-0612-5</ArticleId><ArticleId IdType="pmc">PMC5697110</ArticleId><ArticleId IdType="pubmed">29157280</ArticleId></ArticleIdList></Reference><Reference><Citation>Anagnostis, P., Galanis, P., Chatzistergiou, V., Stevenson, J.C., Godsland, I.F., Lambrinoudaki, I.et al. (2017) The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: a systematic review and meta-analysis. Maturitas 99, 27&#x2013;36 10.1016/j.maturitas.2017.02.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.maturitas.2017.02.009</ArticleId><ArticleId IdType="pubmed">28364865</ArticleId></ArticleIdList></Reference><Reference><Citation>Chennamsetty, I., Claudel, T., Kostner, K.M., Baghdasaryan, A., Kratky, D., Levak-Frank, S.et al. (2011) Farnesoid X receptor represses hepatic human APOA gene expression. J. Clin. Invest. 121, 3724&#x2013;3734 10.1172/JCI45277</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI45277</ArticleId><ArticleId IdType="pmc">PMC3163948</ArticleId><ArticleId IdType="pubmed">21804189</ArticleId></ArticleIdList></Reference><Reference><Citation>Chennamsetty, I., Claudel, T., Kostner, K.M., Trauner, M. and Kostner, G.M. (2012) FGF19 signaling cascade suppresses APOA gene expression. Arterioscler. Thromb. Vasc. Biol. 32, 1220&#x2013;1227 10.1161/ATVBAHA.111.243055</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.111.243055</ArticleId><ArticleId IdType="pubmed">22267484</ArticleId></ArticleIdList></Reference><Reference><Citation>Wade, D.P., Clarke, J.G., Lindahl, G.E., Liu, A.C., Zysow, B.R., Meer, K.et al. (1993) 5&#x2019; control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family. Proc. Natl Acad. Sci. U.S.A. 90, 1369&#x2013;1373 10.1073/pnas.90.4.1369</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.4.1369</ArticleId><ArticleId IdType="pmc">PMC45874</ArticleId><ArticleId IdType="pubmed">7679504</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller, N., Schulte, D.M., Turk, K., Freitag-Wolf, S., Hampe, J., Zeuner, R.et al. (2015) IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J. Lipid Res. 56, 1034&#x2013;1042 10.1194/jlr.P052209</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.P052209</ArticleId><ArticleId IdType="pmc">PMC4409280</ArticleId><ArticleId IdType="pubmed">25713100</ArticleId></ArticleIdList></Reference><Reference><Citation>Scipione, C.A., Sayegh, S.E., Romagnuolo, R., Tsimikas, S., Marcovina, S.M., Boffa, M.B.et al. (2015) Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a). J. Lipid Res. 56, 2273&#x2013;2285 10.1194/jlr.M060210</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M060210</ArticleId><ArticleId IdType="pmc">PMC4655984</ArticleId><ArticleId IdType="pubmed">26474593</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriarty, P.M., Gorby, L.K., Stroes, E.S., Kastelein, J.P., Davidson, M. and Tsimikas, S. (2020) Lipoprotein(a) and its potential association with thrombosis and inflammation in COVID-19: a testable hypothesis. Curr. Atheroscler. Rep. 22, 48 10.1007/s11883-020-00867-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11883-020-00867-3</ArticleId><ArticleId IdType="pmc">PMC7381416</ArticleId><ArticleId IdType="pubmed">32710255</ArticleId></ArticleIdList></Reference><Reference><Citation>White, A.L. and Lanford, R.E. (1995) Biosynthesis and metabolism of lipoprotein (a). Curr. Opin. Lipidol. 6, 75&#x2013;80 10.1097/00041433-199504000-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00041433-199504000-00003</ArticleId><ArticleId IdType="pubmed">7773571</ArticleId></ArticleIdList></Reference><Reference><Citation>White, A.L., Rainwater, D.L. and Lanford, R.E. (1993) Intracellular maturation of apolipoprotein[a] and assembly of lipoprotein[a] in primary baboon hepatocytes. J. Lipid Res. 34, 509&#x2013;517 10.1016/S0022-2275(20)40742-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2275(20)40742-4</ArticleId><ArticleId IdType="pubmed">8468534</ArticleId></ArticleIdList></Reference><Reference><Citation>White, A.L., Guerra, B. and Lanford, R.E. (1997) Influence of allelic variation on apolipoprotein(a) folding in the endoplasmic reticulum. J. Biol. Chem. 272, 5048&#x2013;5055 10.1074/jbc.272.8.5048</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.8.5048</ArticleId><ArticleId IdType="pubmed">9030568</ArticleId></ArticleIdList></Reference><Reference><Citation>White, A.L., Hixson, J.E., Rainwater, D.L. and Lanford, R.E. (1994) Molecular basis for &#x201c;null&#x201d; lipoprotein(a) phenotypes and the influence of apolipoprotein(a) size on plasma lipoprotein(a) level in the baboon. J. Biol. Chem. 269, 9060&#x2013;9066 10.1016/S0021-9258(17)37076-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(17)37076-X</ArticleId><ArticleId IdType="pubmed">8132643</ArticleId></ArticleIdList></Reference><Reference><Citation>White, A.L., Guerra, B., Wang, J. and Lanford, R.E. (1999) Presecretory degradation of apolipoprotein [a] is mediated by the proteasome pathway. J. Lipid Res. 40, 275&#x2013;286 10.1016/S0022-2275(20)33367-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2275(20)33367-8</ArticleId><ArticleId IdType="pubmed">9925657</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, J. and White, A.L. (1999) Role of N-linked glycans, chaperone interactions and proteasomes in the intracellular targeting of apolipoprotein(a). Biochem. Soc. Trans. 27, 453&#x2013;458 10.1042/bst0270453</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bst0270453</ArticleId><ArticleId IdType="pubmed">10917619</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker, L., McLeod, R.S., Marcovina, S.M., Yao, Z. and Koschinsky, M.L. (2001) Identification of a critical lysine residue in apolipoprotein B-100 that mediates noncovalent interaction with apolipoprotein(a). J. Biol. Chem. 276, 36155&#x2013;36162 10.1074/jbc.M104789200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M104789200</ArticleId><ArticleId IdType="pubmed">11473115</ArticleId></ArticleIdList></Reference><Reference><Citation>White, A.L. and Lanford, R.E. (1994) Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes. J. Biol. Chem. 269, 28716&#x2013;28723 10.1016/S0021-9258(19)61964-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(19)61964-2</ArticleId><ArticleId IdType="pubmed">7961823</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker, L., Nesheim, M.E. and Koschinsky, M.L. (2006) Catalysis of covalent Lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation. Biochemistry 45, 9919&#x2013;9928 10.1021/bi060283t</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi060283t</ArticleId><ArticleId IdType="pubmed">16893192</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes-Soffer, G., Ginsberg, H.N. and Ramakrishnan, R. (2017) The metabolism of lipoprotein (a): an ever-evolving story. J. Lipid Res. 58, 1756&#x2013;1764 10.1194/jlr.R077693</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.R077693</ArticleId><ArticleId IdType="pmc">PMC5580906</ArticleId><ArticleId IdType="pubmed">28720561</ArticleId></ArticleIdList></Reference><Reference><Citation>Su, W., Campos, H., Judge, H., Walsh, B.W. and Sacks, F.M. (1998) Metabolism of Apo(a) and ApoB100 of lipoprotein(a) in women: effect of postmenopausal estrogen replacement. J. Clin. Endocrinol. Metab. 83, 3267&#x2013;3276 10.1210/jcem.83.9.5116</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jcem.83.9.5116</ArticleId><ArticleId IdType="pubmed">9745440</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenner, J.L., Seman, L.J., Millar, J.S., Lamon-Fava, S., Welty, F.K., Dolnikowski, G.G.et al. (2005) The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings. Metabolism 54, 361&#x2013;369 10.1016/j.metabol.2004.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2004.10.001</ArticleId><ArticleId IdType="pubmed">15736114</ArticleId></ArticleIdList></Reference><Reference><Citation>Diffenderfer, M.R., Lamon-Fava, S., Marcovina, S.M., Barrett, P.H., Lel, J., Dolnikowski, G.G.et al. (2016) Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a). Metabolism 65, 381&#x2013;390 10.1016/j.metabol.2015.10.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2015.10.031</ArticleId><ArticleId IdType="pmc">PMC4795479</ArticleId><ArticleId IdType="pubmed">26975530</ArticleId></ArticleIdList></Reference><Reference><Citation>Frischmann, M.E., Ikewaki, K., Trenkwalder, E., Lamina, C., Dieplinger, B., Soufi, M.et al. (2012) In vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a). Atherosclerosis 225, 322&#x2013;327 10.1016/j.atherosclerosis.2012.09.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2012.09.031</ArticleId><ArticleId IdType="pubmed">23099120</ArticleId></ArticleIdList></Reference><Reference><Citation>Demant, T., Seeberg, K., Bedynek, A. and Seidel, D. (2001) The metabolism of lipoprotein(a) and other apolipoprotein B-containing lipoproteins: a kinetic study in humans. Atherosclerosis 157, 325&#x2013;339 10.1016/S0021-9150(00)00732-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9150(00)00732-2</ArticleId><ArticleId IdType="pubmed">11472732</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi, E.M., Watts, G.F., Chan, D.C., Pang, J., Tenneti, V.S., Hamilton, S.J.et al. (2015) Effects of extended-release niacin on the postprandial metabolism of Lp(a) and apoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 35, 2686&#x2013;2693 10.1161/ATVBAHA.115.306136</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.115.306136</ArticleId><ArticleId IdType="pubmed">26515419</ArticleId></ArticleIdList></Reference><Reference><Citation>Youssef, A., Clark, J.R., Marcovina, S.M., Boffa, M.B. and Koschinsky, M.L. (2022) Apo(a) and apoB interact noncovalently within hepatocytes: implications for regulation of Lp(a) levels by modulation of apoB secretion. Arterioscler. Thromb. Vasc. Biol. 42, 289&#x2013;304 10.1161/ATVBAHA.121.317335</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.121.317335</ArticleId><ArticleId IdType="pubmed">35045727</ArticleId></ArticleIdList></Reference><Reference><Citation>Rader, D.J., Mann, W.A., Cain, W., Kraft, H.G., Usher, D., Zech, L.A.et al. (1995) The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J. Clin. Invest. 95, 1403&#x2013;1408 10.1172/JCI117794</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI117794</ArticleId><ArticleId IdType="pmc">PMC441483</ArticleId><ArticleId IdType="pubmed">7883987</ArticleId></ArticleIdList></Reference><Reference><Citation>Cain, W.J., Millar, J.S., Himebauch, A.S., Tietge, U.J., Maugeais, C., Usher, D.et al. (2005) Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. J. Lipid Res. 46, 2681&#x2013;2691 10.1194/jlr.M500249-JLR200</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M500249-JLR200</ArticleId><ArticleId IdType="pubmed">16150825</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover-Plow, J. and Huang, M. (2013) Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism 62, 479&#x2013;491 10.1016/j.metabol.2012.07.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2012.07.024</ArticleId><ArticleId IdType="pmc">PMC3547132</ArticleId><ArticleId IdType="pubmed">23040268</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemello, K., Chan, D.C., Lambert, G. and Watts, G.F. (2022) Recent advances in demystifying the metabolism of lipoprotein(a). Atherosclerosis 349, 82&#x2013;91 10.1016/j.atherosclerosis.2022.04.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2022.04.002</ArticleId><ArticleId IdType="pubmed">35606080</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam, S.P., Zhang, X. and Koschinsky, M.L. (1996) Interaction of a recombinant form of apolipoprotein[a] with human fibroblasts and with the human hepatoma cell line HepG2. J. Lipid Res. 37, 518&#x2013;533 10.1016/S0022-2275(20)37595-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2275(20)37595-7</ArticleId><ArticleId IdType="pubmed">8728315</ArticleId></ArticleIdList></Reference><Reference><Citation>Romagnuolo, R., Scipione, C.A., Boffa, M.B., Marcovina, S.M., Seidah, N.G. and Koschinsky, M.L. (2015) Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J. Biol. Chem. 290, 11649&#x2013;11662 10.1074/jbc.M114.611988</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.611988</ArticleId><ArticleId IdType="pmc">PMC4416867</ArticleId><ArticleId IdType="pubmed">25778403</ArticleId></ArticleIdList></Reference><Reference><Citation>Romagnuolo, R., Scipione, C.A., Marcovina, S.M., Gemin, M., Seidah, N.G., Boffa, M.B.et al. (2017) Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9. PLoS One 12, e0180869 10.1371/journal.pone.0180869</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0180869</ArticleId><ArticleId IdType="pmc">PMC5531514</ArticleId><ArticleId IdType="pubmed">28750079</ArticleId></ArticleIdList></Reference><Reference><Citation>Raal, F.J., Giugliano, R.P., Sabatine, M.S., Koren, M.J., Blom, D., Seidah, N.G.et al. (2016) PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. J. Lipid Res. 57, 1086&#x2013;1096 10.1194/jlr.P065334</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.P065334</ArticleId><ArticleId IdType="pmc">PMC4878192</ArticleId><ArticleId IdType="pubmed">27102113</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsimikas, S., Gordts, P., Nora, C., Yeang, C. and Witztum, J.L. (2020) Statin therapy increases lipoprotein(a) levels. Eur. Heart J. 41, 2275&#x2013;2284 10.1093/eurheartj/ehz310</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz310</ArticleId><ArticleId IdType="pubmed">31111151</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai, N.R., Kohli, P., Giugliano, R.P., O'Donoghue, M.L., Somaratne, R., Zhou, J.et al. (2013) AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation 128, 962&#x2013;969 10.1161/CIRCULATIONAHA.113.001969</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.001969</ArticleId><ArticleId IdType="pubmed">23884353</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaudet, D., Kereiakes, D.J., McKenney, J.M., Roth, E.M., Hanotin, C., Gipe, D.et al. (2014) Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150&#x2005;mg every two weeks dosing from phase 2 trials). Am. J. Cardiol. 114, 711&#x2013;715 10.1016/j.amjcard.2014.05.060</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2014.05.060</ArticleId><ArticleId IdType="pubmed">25060413</ArticleId></ArticleIdList></Reference><Reference><Citation>Roubtsova, A., Scipione, C.A., Garcon, D., Boffa, M.B., Seidah, N.G., Koschinsky, M.L.et al. (2023) Surface LDLR is a major receptor for lipoprotein(a) clearance in male mice lacking PCSK9. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1868, 159288 10.1016/j.bbalip.2023.159288</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2023.159288</ArticleId><ArticleId IdType="pubmed">36708961</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts, G.F., Chan, D.C., Somaratne, R., Wasserman, S.M., Scott, R., Marcovina, S.M.et al. (2018) Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur. Heart J. 39, 2577&#x2013;2585 10.1093/eurheartj/ehy122</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy122</ArticleId><ArticleId IdType="pubmed">29566128</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts, G.F., Chan, D.C., Pang, J., Ma, L., Ying, Q., Aggarwal, S.et al. (2020) PCSK9 inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a). Metabolism 107, 154221 10.1016/j.metabol.2020.154221</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2020.154221</ArticleId><ArticleId IdType="pubmed">32240727</ArticleId></ArticleIdList></Reference><Reference><Citation>Ying, Q., Chan, D.C., Pang, J., Marcovina, S.M., Barrett, P.H.R. and Watts, G.F. (2022) PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statin-treated patients with very high apolipoprotein(a) concentration. J. Intern. Med. 291, 870&#x2013;876 10.1111/joim.13457</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13457</ArticleId><ArticleId IdType="pubmed">35112754</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmann, S.L., Eaton, D.L., Brown, M.S., McConathy, W.J., Goldstein, J.L. and Hammer, R.E. (1990) Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J. Clin. Invest. 85, 1542&#x2013;1547 10.1172/JCI114602</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI114602</ArticleId><ArticleId IdType="pmc">PMC296603</ArticleId><ArticleId IdType="pubmed">2139667</ArticleId></ArticleIdList></Reference><Reference><Citation>Marz, W., Beckmann, A., Scharnagl, H., Siekmeier, R., Mondorf, U., Held, I., et al. (1993) Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. FEBS Lett. 325, 271&#x2013;275 10.1016/0014-5793(93)81087-G</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(93)81087-G</ArticleId><ArticleId IdType="pubmed">8319809</ArticleId></ArticleIdList></Reference><Reference><Citation>Reblin, T., Niemeier, A., Meyer, N., Willnow, T.E., Kronenberg, F., Dieplinger, H.et al. (1997) Cellular uptake of lipoprotein[a] by mouse embryonic fibroblasts via the LDL receptor and the LDL receptor-related protein. J. Lipid Res. 38, 2103&#x2013;2110 10.1016/S0022-2275(20)37140-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2275(20)37140-6</ArticleId><ArticleId IdType="pubmed">9374132</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottalico, L.A., Keesler, G.A., Fless, G.M. and Tabas, I. (1993) Cholesterol loading of macrophages leads to marked enhancement of native lipoprotein(a) and apoprotein(a) internalization and degradation. J. Biol. Chem. 268, 8569&#x2013;8573 10.1016/S0021-9258(18)52913-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)52913-6</ArticleId><ArticleId IdType="pubmed">8473302</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, X.P., Amar, M.J., Vaisman, B., Bocharov, A.V., Vishnyakova, T.G., Freeman, L.A.et al. (2013) Scavenger receptor-BI is a receptor for lipoprotein(a). J. Lipid Res. 54, 2450&#x2013;2457 10.1194/jlr.M038877</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M038877</ArticleId><ArticleId IdType="pmc">PMC3735942</ArticleId><ArticleId IdType="pubmed">23812625</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, X., Sethi, A., Yanek, L.R., Knapper, C., Nordestgaard, B.G., Tybjaerg-Hansen, A.et al. (2016) SCARB1 gene variants are associated with the phenotype of combined high high-density lipoprotein cholesterol and high lipoprotein (a). Circ. Cardiovasc. Genet. 9, 408&#x2013;418 10.1161/CIRCGENETICS.116.001402</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCGENETICS.116.001402</ArticleId><ArticleId IdType="pubmed">27651445</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemeier, A., Willnow, T., Dieplinger, H., Jacobsen, C., Meyer, N., Hilpert, J.et al. (1999) Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro. Arterioscler. Thromb. Vasc. Biol. 19, 552&#x2013;561 10.1161/01.ATV.19.3.552</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.19.3.552</ArticleId><ArticleId IdType="pubmed">10073957</ArticleId></ArticleIdList></Reference><Reference><Citation>Albers, J.J., Koschinsky, M.L. and Marcovina, S.M. (2007) Evidence mounts for a role of the kidney in lipoprotein(a) catabolism. Kidney Int. 71, 961&#x2013;962 10.1038/sj.ki.5002240</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ki.5002240</ArticleId><ArticleId IdType="pubmed">17495935</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma, M., Redpath, G.M., Williams, M.J. and McCormick, S.P. (2017) Recycling of apolipoprotein(a) after PlgRKT-mediated endocytosis of lipoprotein(a). Circ. Res. 120, 1091&#x2013;1102 10.1161/CIRCRESAHA.116.310272</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.116.310272</ArticleId><ArticleId IdType="pubmed">28003220</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqui, H., Deo, N., Rutledge, M.T., Williams, M.J.A., Redpath, G.M.I. and McCormick, S.P.A. (2023) Plasminogen receptors promote lipoprotein(a) uptake by enhancing surface binding and facilitating macropinocytosis. Arterioscler. Thromb. Vasc. Biol. 43, 1851&#x2013;1866 10.1161/ATVBAHA.123.319344</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.123.319344</ArticleId><ArticleId IdType="pmc">PMC10521804</ArticleId><ArticleId IdType="pubmed">37589135</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr, M.C. and Teasdale, R.D. (2009) Defining macropinocytosis. Traffic 10, 364&#x2013;371 10.1111/j.1600-0854.2009.00878.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0854.2009.00878.x</ArticleId><ArticleId IdType="pubmed">19192253</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack, S., Coassin, S., Rueedi, R., Yousri, N.A., Seppala, I., Gieger, C.et al. (2017) A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms. J. Lipid Res. 58, 1834&#x2013;1844 10.1194/jlr.M076232</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M076232</ArticleId><ArticleId IdType="pmc">PMC5580897</ArticleId><ArticleId IdType="pubmed">28512139</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta, A., Jain, V., Saeed, A., Saseen, J.J., Gulati, M., Ballantyne, C.M.et al. (2022) Lipoprotein(a) and ethnicities. Atherosclerosis 349, 42&#x2013;52 10.1016/j.atherosclerosis.2022.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2022.04.005</ArticleId><ArticleId IdType="pubmed">35606075</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanktree, M.B., Anand, S.S., Yusuf, S., Hegele, R.A. and Investigators, S. (2010) Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circ. Cardiovasc. Genet. 3, 39&#x2013;46 10.1161/CIRCGENETICS.109.907642</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCGENETICS.109.907642</ArticleId><ArticleId IdType="pubmed">20160194</ArticleId></ArticleIdList></Reference><Reference><Citation>Coassin, S., Erhart, G., Weissensteiner, H., Eca Guimaraes de Araujo, M., Lamina, C., Schonherr, S.et al. (2017) A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction. Eur. Heart J. 38, 1823&#x2013;1831 10.1093/eurheartj/ehx174</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehx174</ArticleId><ArticleId IdType="pmc">PMC5837733</ArticleId><ArticleId IdType="pubmed">28444229</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Maio, S., Gruneis, R., Streiter, G., Lamina, C., Maglione, M., Schoenherr, S.et al. (2020) Investigation of a nonsense mutation located in the complex KIV-2 copy number variation region of apolipoprotein(a) in 10,910 individuals. Genome Med. 12, 74 10.1186/s13073-020-00771-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-020-00771-0</ArticleId><ArticleId IdType="pmc">PMC7442989</ArticleId><ArticleId IdType="pubmed">32825847</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoekstra, M., Chen, H.Y., Rong, J., Dufresne, L., Yao, J., Guo, X.et al. (2021) Genome-wide association study highlights APOH as a novel locus for lipoprotein(a) levels-brief report. Arterioscler. Thromb. Vasc. Biol. 41, 458&#x2013;464 10.1161/ATVBAHA.120.314965</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.120.314965</ArticleId><ArticleId IdType="pmc">PMC7769958</ArticleId><ArticleId IdType="pubmed">33115273</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriarty, P.M., Varvel, S.A., Gordts, P.L., McConnell, J.P. and Tsimikas, S. (2017) Lipoprotein(a) mass levels increase significantly according to APOE genotype: an analysis of 431 239 patients. Arterioscler. Thromb. Vasc. Biol. 37, 580&#x2013;588 10.1161/ATVBAHA.116.308704</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.116.308704</ArticleId><ArticleId IdType="pmc">PMC5323356</ArticleId><ArticleId IdType="pubmed">28062489</ArticleId></ArticleIdList></Reference><Reference><Citation>Kochl, S., Fresser, F., Lobentanz, E., Baier, G. and Utermann, G. (1997) Novel interaction of apolipoprotein(a) with beta-2 glycoprotein I mediated by the kringle IV domain. Blood 90, 1482&#x2013;1489 10.1182/blood.V90.4.1482</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V90.4.1482</ArticleId><ArticleId IdType="pubmed">9269765</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholls, S.J., Ruotolo, G., Brewer, H.B., Wang, M.D., Liu, L., Willey, M.B.et al. (2016) Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. J. Clin. Lipidol. 10, 519&#x2013;527 e4 10.1016/j.jacl.2015.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacl.2015.11.014</ArticleId><ArticleId IdType="pubmed">27206939</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas, T., Zhou, H., Karmally, W., Ramakrishnan, R., Holleran, S., Liu, Y.et al. (2017) CETP (cholesteryl ester transfer protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects. Arterioscler. Thromb. Vasc. Biol. 37, 1770&#x2013;1775 10.1161/ATVBAHA.117.309549</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.117.309549</ArticleId><ArticleId IdType="pmc">PMC5567403</ArticleId><ArticleId IdType="pubmed">28729361</ArticleId></ArticleIdList></Reference><Reference><Citation>Arsenault, B.J. and Kamstrup, P.R. (2022) Lipoprotein(a) and cardiovascular and valvular diseases: a genetic epidemiological perspective. Atherosclerosis 349, 7&#x2013;16 10.1016/j.atherosclerosis.2022.04.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2022.04.015</ArticleId><ArticleId IdType="pubmed">35606078</ArticleId></ArticleIdList></Reference><Reference><Citation>Boffa, M.B. (2022) Beyond fibrinolysis: the confounding role of Lp(a) in thrombosis. Atherosclerosis 349, 72&#x2013;81 10.1016/j.atherosclerosis.2022.04.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2022.04.009</ArticleId><ArticleId IdType="pubmed">35606079</ArticleId></ArticleIdList></Reference><Reference><Citation>Koschinsky, M.L. and Boffa, M.B. (2022) Oxidized phospholipid modification of lipoprotein(a): epidemiology, biochemistry and pathophysiology. Atherosclerosis 349, 92&#x2013;100 10.1016/j.atherosclerosis.2022.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2022.04.001</ArticleId><ArticleId IdType="pubmed">35606081</ArticleId></ArticleIdList></Reference><Reference><Citation>Boffa, M.B. and Koschinsky, M.L. (2019) Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nat. Rev. Cardiol. 16, 305&#x2013;318 10.1038/s41569-018-0153-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-018-0153-2</ArticleId><ArticleId IdType="pubmed">30675027</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeang, C., Cotter, B. and Tsimikas, S. (2016) Experimental animal models evaluating the causal role of lipoprotein(a) in atherosclerosis and aortic stenosis. Cardiovasc. Drugs Ther. 30, 75&#x2013;85 10.1007/s10557-015-6634-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10557-015-6634-1</ArticleId><ArticleId IdType="pubmed">26780907</ArticleId></ArticleIdList></Reference><Reference><Citation>Assini, J.M., Clark, J.R., Youssef, A., Xing, C., Doerfler, A.M., Park, S.H.et al. (2023) High levels of lipoprotein(a) in transgenic mice exacerbate atherosclerosis and promote vulnerable plaque features in a sex-specific manner. Atherosclerosis 384, 117150 10.1016/j.atherosclerosis.2023.05.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2023.05.019</ArticleId><ArticleId IdType="pubmed">37290980</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamstrup, P.R., Tybjaerg-Hansen, A. and Nordestgaard, B.G. (2012) Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis. Arterioscler. Thromb. Vasc. Biol. 32, 1732&#x2013;1741 10.1161/ATVBAHA.112.248765</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.112.248765</ArticleId><ArticleId IdType="pubmed">22516069</ArticleId></ArticleIdList></Reference><Reference><Citation>Sangrar, W., Bajzar, L., Nesheim, M.E. and Koschinsky, M.L. (1995) Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation. Biochemistry 34, 5151&#x2013;5157 10.1021/bi00015a028</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi00015a028</ArticleId><ArticleId IdType="pubmed">7711034</ArticleId></ArticleIdList></Reference><Reference><Citation>Hancock, M.A., Boffa, M.B., Marcovina, S.M., Nesheim, M.E. and Koschinsky, M.L. (2003) Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J. Biol. Chem. 278, 23260&#x2013;23269 10.1074/jbc.M302780200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M302780200</ArticleId><ArticleId IdType="pubmed">12697748</ArticleId></ArticleIdList></Reference><Reference><Citation>Scipione, C.A., McAiney, J.T., Simard, D.J., Bazzi, Z.A., Gemin, M., Romagnuolo, R.et al. (2017) Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a). J. Thromb. Haemost. 15, 1834&#x2013;1844 10.1111/jth.13759</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.13759</ArticleId><ArticleId IdType="pubmed">28632940</ArticleId></ArticleIdList></Reference><Reference><Citation>Boffa, M.B., Marar, T.T., Yeang, C., Viney, N.J., Xia, S., Witztum, J.L.et al. (2019) Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis. J. Lipid Res. 60, 2082&#x2013;2089 10.1194/jlr.P094763</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.P094763</ArticleId><ArticleId IdType="pmc">PMC6889713</ArticleId><ArticleId IdType="pubmed">31551368</ArticleId></ArticleIdList></Reference><Reference><Citation>Caplice, N.M., Panetta, C., Peterson, T.E., Kleppe, L.S., Mueske, C.S., Kostner, G.M.et al. (2001) Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 98, 2980&#x2013;2987 10.1182/blood.V98.10.2980</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V98.10.2980</ArticleId><ArticleId IdType="pubmed">11698280</ArticleId></ArticleIdList></Reference><Reference><Citation>Etingin, O.R., Hajjar, D.P., Hajjar, K.A., Harpel, P.C. and Nachman, R.L. (1991) Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J. Biol. Chem. 266, 2459&#x2013;2465 10.1016/S0021-9258(18)52266-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)52266-3</ArticleId><ArticleId IdType="pubmed">1824942</ArticleId></ArticleIdList></Reference><Reference><Citation>Rand, M.L., Sangrar, W., Hancock, M.A., Taylor, D.M., Marcovina, S.M., Packham, M.A.et al. (1998) Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler. Thromb. Vasc. Biol. 18, 1393&#x2013;1399 10.1161/01.ATV.18.9.1393</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.18.9.1393</ArticleId><ArticleId IdType="pubmed">9743227</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui, K., Wang, H.Y., Yin, D., Zhu, C., Song, W., Wang, H.et al. (2021) Benefit and risk of prolonged dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stents in patients with elevated lipoprotein(a) concentrations. Front. Cardiovasc. Med. 8, 807925 10.3389/fcvm.2021.807925</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.807925</ArticleId><ArticleId IdType="pmc">PMC8720964</ArticleId><ArticleId IdType="pubmed">34988134</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacaze, P., Bakshi, A., Riaz, M., Polekhina, G., Owen, A., Bhatia, H.S.et al. (2022) Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes. J. Am. Coll. Cardiol. 80, 1287&#x2013;1298 10.1016/j.jacc.2022.07.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.07.027</ArticleId><ArticleId IdType="pmc">PMC10025998</ArticleId><ArticleId IdType="pubmed">36175048</ArticleId></ArticleIdList></Reference><Reference><Citation>Langsted, A., Kamstrup, P.R. and Nordestgaard, B.G. (2017) High lipoprotein(a) and low risk of major bleeding in brain and airways in the general population: a Mendelian randomization study. Clin. Chem. 63, 1714&#x2013;1723 10.1373/clinchem.2017.276931</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2017.276931</ArticleId><ArticleId IdType="pubmed">28877919</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsimikas, S., Bergmark, C., Beyer, R.W., Patel, R., Pattison, J., Miller, E.et al. (2003) Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J. Am. Coll. Cardiol. 41, 360&#x2013;370 10.1016/S0735-1097(02)02769-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(02)02769-9</ArticleId><ArticleId IdType="pubmed">12575961</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsimikas, S., Lau, H.K., Han, K.R., Shortal, B., Miller, E.R., Segev, A.et al. (2004) Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 109, 3164&#x2013;3170 10.1161/01.CIR.0000130844.01174.55</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000130844.01174.55</ArticleId><ArticleId IdType="pubmed">15184281</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsimikas, S., Brilakis, E.S., Miller, E.R., McConnell, J.P., Lennon, R.J., Kornman, K.S.et al. (2005) Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N. Engl. J. Med. 353, 46&#x2013;57 10.1056/NEJMoa043175</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa043175</ArticleId><ArticleId IdType="pubmed">16000355</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsimikas, S., Kiechl, S., Willeit, J., Mayr, M., Miller, E.R., Kronenberg, F.et al. (2006) Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J. Am. Coll. Cardiol. 47, 2219&#x2013;2228 10.1016/j.jacc.2006.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2006.03.001</ArticleId><ArticleId IdType="pubmed">16750687</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodenburg, J., Vissers, M.N., Wiegman, A., Miller, E.R., Ridker, P.M., Witztum, J.L.et al. (2006) Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J. Am. Coll. Cardiol. 47, 1803&#x2013;1810 10.1016/j.jacc.2005.12.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2005.12.047</ArticleId><ArticleId IdType="pubmed">16682304</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraley, A.E., Schwartz, G.G., Olsson, A.G., Kinlay, S., Szarek, M., Rifai, N.et al. (2009) Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. J. Am. Coll. Cardiol. 53, 2186&#x2013;2196 10.1016/j.jacc.2009.02.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2009.02.041</ArticleId><ArticleId IdType="pubmed">19497447</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiechl, S., Willeit, J., Mayr, M., Viehweider, B., Oberhollenzer, M., Kronenberg, F.et al. (2007) Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler. Thromb. Vasc. Biol. 27, 1788&#x2013;1795 10.1161/ATVBAHA.107.145805</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.107.145805</ArticleId><ArticleId IdType="pubmed">17541022</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravandi, A., Boekholdt, S.M., Mallat, Z., Talmud, P.J., Kastelein, J.J., Wareham, N.J.et al. (2011) Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J. Lipid Res. 52, 1829&#x2013;1836 10.1194/jlr.M015776</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M015776</ArticleId><ArticleId IdType="pmc">PMC3173004</ArticleId><ArticleId IdType="pubmed">21821825</ArticleId></ArticleIdList></Reference><Reference><Citation>Nsaibia, M.J., Mahmut, A., Boulanger, M.C., Arsenault, B.J., Bouchareb, R., Simard, S.et al. (2016) Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease. J. Intern. Med. 280, 509&#x2013;517 10.1111/joim.12519</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.12519</ArticleId><ArticleId IdType="pubmed">27237700</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouchareb, R., Mahmut, A., Nsaibia, M.J., Boulanger, M.C., Dahou, A., Lepine, J.L.et al. (2015) Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve. Circulation 132, 677&#x2013;690 10.1161/CIRCULATIONAHA.115.016757</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.115.016757</ArticleId><ArticleId IdType="pubmed">26224810</ArticleId></ArticleIdList></Reference><Reference><Citation>Rath, M., Niendorf, A., Reblin, T., Dietel, M., Krebber, H.J. and Beisiegel, U. (1989) Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 9, 579&#x2013;592 10.1161/01.ATV.9.5.579</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.9.5.579</ArticleId><ArticleId IdType="pubmed">2528948</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dijk, R.A., Kolodgie, F., Ravandi, A., Leibundgut, G., Hu, P.P., Prasad, A.et al. (2012) Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J. Lipid Res. 53, 2773&#x2013;2790 10.1194/jlr.P030890</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.P030890</ArticleId><ArticleId IdType="pmc">PMC3494262</ArticleId><ArticleId IdType="pubmed">22969153</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Valk, F.M., Bekkering, S., Kroon, J., Yeang, C., Van den Bossche, J., van Buul, J.D.et al. (2016) Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation 134, 611&#x2013;624 10.1161/CIRCULATIONAHA.116.020838</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.116.020838</ArticleId><ArticleId IdType="pmc">PMC4995139</ArticleId><ArticleId IdType="pubmed">27496857</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnitzler, J.G., Hoogeveen, R.M., Ali, L., Prange, K.H.M., Waissi, F., van Weeghel, M.et al. (2020) Atherogenic lipoprotein(a) increases vascular glycolysis, thereby facilitating inflammation and leukocyte extravasation. Circ. Res. 126, 1346&#x2013;1359 10.1161/CIRCRESAHA.119.316206</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.119.316206</ArticleId><ArticleId IdType="pmc">PMC7208285</ArticleId><ArticleId IdType="pubmed">32160811</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho, T., Jung, Y. and Koschinsky, M.L. (2008) Apolipoprotein(a), through its strong lysine-binding site in KIV(10&#x2019;), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J. Biol. Chem. 283, 30503&#x2013;30512 10.1074/jbc.M802648200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M802648200</ArticleId><ArticleId IdType="pmc">PMC2662143</ArticleId><ArticleId IdType="pubmed">18776185</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho, T., Romagnuolo, R., Scipione, C., Boffa, M.B. and Koschinsky, M.L. (2013) Apolipoprotein(a) stimulates nuclear translocation of beta-catenin: a novel pathogenic mechanism for lipoprotein(a). Mol. Biol. Cell 24, 210&#x2013;221 10.1091/mbc.e12-08-0637</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.e12-08-0637</ArticleId><ArticleId IdType="pmc">PMC3564524</ArticleId><ArticleId IdType="pubmed">23243000</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, K.H., Tsimikas, S., Pawade, T., Kroon, J., Jenkins, W.S.A., Doris, M.K.et al. (2019) Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J. Am. Coll. Cardiol. 73, 2150&#x2013;2162 10.1016/j.jacc.2019.01.070</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2019.01.070</ArticleId><ArticleId IdType="pmc">PMC6494952</ArticleId><ArticleId IdType="pubmed">31047003</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz, G.G. and Ballantyne, C.M. (2022) Existing and emerging strategies to lower lipoprotein(a). Atherosclerosis 349, 110&#x2013;122 10.1016/j.atherosclerosis.2022.04.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2022.04.020</ArticleId><ArticleId IdType="pubmed">35606071</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos, R.D., Raal, F.J., Catapano, A.L., Witztum, J.L., Steinhagen-Thiessen, E. and Tsimikas, S. (2015) Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler. Thromb. Vasc. Biol. 35, 689&#x2013;699 10.1161/ATVBAHA.114.304549</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.114.304549</ArticleId><ArticleId IdType="pmc">PMC4344404</ArticleId><ArticleId IdType="pubmed">25614280</ArticleId></ArticleIdList></Reference><Reference><Citation>Samaha, F.F., McKenney, J., Bloedon, L.T., Sasiela, W.J. and Rader, D.J. (2008) Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med. 5, 497&#x2013;505 10.1038/ncpcardio1250</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncpcardio1250</ArticleId><ArticleId IdType="pubmed">18506154</ArticleId></ArticleIdList></Reference><Reference><Citation>Parish, S., Hopewell, J.C., Hill, M.R., Marcovina, S., Valdez-Marquez, E., Haynes, R.et al. (2018) Impact of apolipoprotein(a) isoform size on Lp(a) loweriing in the HPS2-THRIVE study. Circ. Genom. Precis. Med. 11, e001696 10.1161/CIRCGEN.117.001696</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCGEN.117.001696</ArticleId><ArticleId IdType="pmc">PMC5841847</ArticleId><ArticleId IdType="pubmed">29449329</ArticleId></ArticleIdList></Reference><Reference><Citation>Boffa, M.B. and Koschinsky, M.L. (2019) Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye? Curr. Opin. Lipidol. 30, 428&#x2013;437 10.1097/MOL.0000000000000641</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOL.0000000000000641</ArticleId><ArticleId IdType="pubmed">31577611</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsimikas, S., Moriarty, P.M. and Stroes, E.S. (2021) Emerging RNA therapeutics to lower blood levels of Lp(a): JACC focus seminar 2/4. J. Am. Coll. Cardiol. 77, 1576&#x2013;1589 10.1016/j.jacc.2021.01.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2021.01.051</ArticleId><ArticleId IdType="pubmed">33766265</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J.C., Baum, S.J., Steinhagen-Thiessen, E.et al. (2020) Lipoprotein(a) reduction in persons with cardiovascular disease. N. Engl. J. Med. 382, 244&#x2013;255 10.1056/NEJMoa1905239</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1905239</ArticleId><ArticleId IdType="pubmed">31893580</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholls, S.J. (2024) Therapeutic potential of lipoprotein(a) inhibitors. Drugs 84, 637&#x2013;643 10.1007/s40265-024-02046-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-024-02046-z</ArticleId><ArticleId IdType="pmc">PMC11196316</ArticleId><ArticleId IdType="pubmed">38849700</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz, N., Perez, C., Escribano, A.M., Sanz, G., Priego, J., Lafuente, C.et al. (2024) Discovery of potent small-molecule inhibitors of lipoprotein(a) formation. Nature 629, 945&#x2013;950 10.1038/s41586-024-07387-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-024-07387-z</ArticleId><ArticleId IdType="pmc">PMC11111404</ArticleId><ArticleId IdType="pubmed">38720069</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholls, S.J., Nissen, S.E., Fleming, C., Urva, S., Suico, J., Berg, P.H.et al. (2023) Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial. JAMA 330, 1042&#x2013;1053 10.1001/jama.2023.16503</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.16503</ArticleId><ArticleId IdType="pmc">PMC10463176</ArticleId><ArticleId IdType="pubmed">37638695</ArticleId></ArticleIdList></Reference><Reference><Citation>Berglund, L. and Ramakrishnan, R. (2004) Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler. Thromb. Vasc. Biol. 24, 2219&#x2013;2226 10.1161/01.ATV.0000144010.55563.63</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.0000144010.55563.63</ArticleId><ArticleId IdType="pmc">PMC3275911</ArticleId><ArticleId IdType="pubmed">15345512</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson, D.P., Jacobson, T.A., Jones, P.H., Koschinsky, M.L., McNeal, C.J., Nordestgaard, B.G.et al. (2019) Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J. Clin. Lipidol. 13, 374&#x2013;392 10.1016/j.jacl.2019.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacl.2019.04.010</ArticleId><ArticleId IdType="pubmed">31147269</ArticleId></ArticleIdList></Reference><Reference><Citation>Arsenault, B.J. (2019) Exposure to low lipoprotein(a) levels: key to healthy aging? J. Am. Coll. Cardiol. 74, 2995&#x2013;2997 10.1016/j.jacc.2019.06.083</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2019.06.083</ArticleId><ArticleId IdType="pubmed">31865967</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung, M.W., Said, M.A., van de Vegte, Y.J., Verweij, N., Dullaart, R.P.F. and van der Harst, P. (2024) Associations of very low lipoprotein(a) levels with risks of new-onset diabetes and non-alcoholic liver disease. Atheroscler. Plus 57, 19&#x2013;25 10.1016/j.athplu.2024.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athplu.2024.07.001</ArticleId><ArticleId IdType="pmc">PMC11300918</ArticleId><ArticleId IdType="pubmed">39109317</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>